Your browser doesn't support javascript.
loading
Lithium: A Promising Anticancer Agent.
Villegas-Vázquez, Edgar Yebrán; Quintas-Granados, Laura Itzel; Cortés, Hernán; González-Del Carmen, Manuel; Leyva-Gómez, Gerardo; Rodríguez-Morales, Miguel; Bustamante-Montes, Lilia Patricia; Silva-Adaya, Daniela; Pérez-Plasencia, Carlos; Jacobo-Herrera, Nadia; Reyes-Hernández, Octavio Daniel; Figueroa-González, Gabriela.
Afiliação
  • Villegas-Vázquez EY; Unidad Multidisciplinaria de Investigación Experimental Zaragoza, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Ciudad de México 09230, Mexico.
  • Quintas-Granados LI; Unidad de Estudios Superiores Tultitlán, Universidad Mexiquense del Bicentenario, Ocoyoacac 54910, Mexico.
  • Cortés H; Laboratorio de Medicina Genómica, Departamento de Genómica, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México 14389, Mexico.
  • González-Del Carmen M; Facultad de Medicina, Universidad Veracruzana, Ciudad Mendoza 94740, Mexico.
  • Leyva-Gómez G; Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
  • Rodríguez-Morales M; Licenciatura en Médico Cirujano, Facultad de Ciencias de la Salud Universidad Anáhuac Norte, Academia de Genética Médica, Naucalpan de Juárez 52786, Mexico.
  • Bustamante-Montes LP; Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  • Silva-Adaya D; Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca de Lerdo 50180, Mexico.
  • Pérez-Plasencia C; Laboratorio Experimental de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México 14269, Mexico.
  • Jacobo-Herrera N; Laboratorio de Genómica, Instituto Nacional de Cancerología (INCan), Ciudad de México 14080, Mexico.
  • Reyes-Hernández OD; Laboratorio de Genómica, Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.
  • Figueroa-González G; Unidad de Bioquímica, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán (INCMNSZ), Ciudad de México 14080, Mexico.
Life (Basel) ; 13(2)2023 Feb 15.
Article em En | MEDLINE | ID: mdl-36836894
ABSTRACT
Lithium is a therapeutic cation used to treat bipolar disorders but also has some important features as an anti-cancer agent. In this review, we provide a general overview of lithium, from its transport into cells, to its innovative administration forms, and based on genomic, transcriptomic, and proteomic data. Lithium formulations such as lithium acetoacetate (LiAcAc), lithium chloride (LiCl), lithium citrate (Li3C6H5O7), and lithium carbonate (Li2CO3) induce apoptosis, autophagy, and inhibition of tumor growth and also participate in the regulation of tumor proliferation, tumor invasion, and metastasis and cell cycle arrest. Moreover, lithium is synergistic with standard cancer therapies, enhancing their anti-tumor effects. In addition, lithium has a neuroprotective role in cancer patients, by improving their quality of life. Interestingly, nano-sized lithium enhances its anti-tumor activities and protects vital organs from the damage caused by lipid peroxidation during tumor development. However, these potential therapeutic activities of lithium depend on various factors, such as the nature and aggressiveness of the tumor, the type of lithium salt, and its form of administration and dosage. Since lithium has been used to treat bipolar disorder, the current study provides an overview of its role in medicine and how this has changed. This review also highlights the importance of this repurposed drug, which appears to have therapeutic cancer potential, and underlines its molecular mechanisms.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article